Survodutide Reconstitution Calculator

Not on the basis of the corpus. It is described as an investigational glucagon receptor/GLP-1 receptor dual agonist in phase 3 obesity programs, including SYNCHRONIZE-1, SYNCHRONIZE-2, and SYNCHRONIZE-MASLD. That means it has late-stage efficacy data, but the cited literature does not establish current FDA approval status.

Current clinical development is centered on obesity, obesity with type 2 diabetes, and obesity with at-risk MASLD/MASH features (Phase 3 RCT). In adults with obesity without diabetes, once-weekly survodutide produced mean body-weight reductions of -12.2% at 3.6 mg and -13.0% at 6.0 mg by week 76 versus -5.4% with placebo. In adults with obesity and at-risk MASLD, 6.0 mg weekly reduced MRI-PDFF liver fat content by at least 30% in 84.2% of participants versus 24.3% with placebo and reduced body weight by -12.2% at week 48 under the efficacy estimand.

It is given as a once-weekly subcutaneous injection (Phase 3 RCT/design papers). Trials used dose escalation up to 3.6 mg or 6.0 mg, rather than starting at the full dose immediately. Practical takeaway: it is not an oral drug in the cited clinical programs; the evidence base is weekly SC injection only.

The main phase 3 obesity trial tested uptitration to 3.6 mg or 6.0 mg once weekly, and both doses outperformed placebo for weight loss at 76 weeks (RCT). The MASLD phase 3 trial used 6.0 mg once weekly (RCT). Community practice would likely mirror GLP-1-family titration logic—slow escalation over weeks to improve GI tolerability rather than racing to the top dose (practitioner consensus).

In the best current human evidence (Phase 3 RCT), mean weight change at week 76 was -12.2% with 3.6 mg and -13.0% with 6.0 mg, versus -5.4% with placebo. The proportion achieving at least 5% weight loss was 72.6%, 71.9%, and 46.3%, respectively. This places survodutide in the “clinically meaningful weight-loss” range, though the 6.0 mg arm did not show a dramatic margin over 3.6 mg in that trial.

Direct head-to-head trials are not provided in the corpus, so any ranking is indirect only (no direct comparator RCT). Mechanistically, survodutide combines GLP-1 receptor agonism with glucagon receptor agonism, whereas semaglutide is GLP-1-only and tirzepatide is GIP/GLP-1. Reviews of obesity pharmacotherapy note that newer agents can produce multisystem benefits beyond weight loss, but the corpus does not provide a direct efficacy comparison table for survodutide vs semaglutide or tirzepatide. Practical summary: it is a distinct incretin-based option with strong phase 3 weight-loss and liver-fat data, but superiority over established alternatives is not proven here.

Gastrointestinal adverse effects are the main signal in phase 3 trials (RCT). In SYNCHRONIZE-1, GI symptoms occurred in 80.9% at 3.6 mg, 89.7% at 6.0 mg, and 47.9% with placebo; they were typically mild to moderate. In the MASLD phase 3 trial, GI adverse events were also the most frequent and were most common during dose escalation, again generally mild to moderate. In practice, nausea, vomiting, decreased appetite, reflux, constipation, and diarrhea are the issues most people plan around (practitioner consensus).

The obesity phase 3 trial reports outcomes through 76 weeks, and the MASLD phase 3 trial through 48 weeks, so human controlled data support use over roughly 1 to 1.5 years depending on indication (RCT). Obesity pharmacotherapy generally behaves like chronic treatment: stopping often risks weight regain, so long-term use is usually the default if efficacy and tolerability are acceptable (practitioner consensus). What is not yet clear from the cited corpus is multi-year durability beyond the completed phase 3 follow-up windows.

Yes, it is being studied specifically in obesity with type 2 diabetes in SYNCHRONIZE-2 (Phase 3 trial program). The design paper for SYNCHRONIZE-2 enrolled adults with BMI at least 27 kg/m² plus T2D, using once-weekly survodutide up-titrated to 3.6 or 6.0 mg or placebo for 76 weeks. The corpus here gives baseline characteristics and trial design, but not final phase 3 efficacy outcomes for the diabetes cohort.

Yes, this is one of the stronger practical use-cases in the corpus (Phase 3 RCT). In adults with obesity and at-risk MASLD, survodutide 6.0 mg weekly was superior to placebo for both liver-fat reduction and body-weight reduction at week 48. Specifically, 84.2% reached at least a 30% reduction in MRI-PDFF liver fat content versus 24.3% with placebo under the efficacy estimand. That is meaningful if the goal is reducing hepatic steatosis along with body weight.

The corpus does not provide storage or travel-handling instructions. Practically, people usually transport peptide pens/syringes in original packaging with temperature protection, carry them in hand luggage, and keep a copy of the prescription or clinic letter for airport security (community protocol). If a dose is likely to be delayed because of travel, weekly dosing makes scheduling easier than daily injectables, but exact missed-dose rules are not established in the cited corpus (community protocol).